

computer readable copy and paper copy of the Sequence Listing are believed to bring the Sequence Listing into full compliance with the sequence rules.

The Examiner has restricted the claims into nine groups:

- Group I: Claims 1-14 and 20-23, drawn to a first product of nucleic acids.
- Group II: Claims 15 and 16, drawn to a second product of nucleic acids comprising a regulatory region.
- Group III: Claims 17-19, drawn to a method to inhibit viral infection.
- Group IV: Claim 24, drawn to a method of screening a compound.
- Group V: Claim 25, drawn to a method of screening a compound for reducing and inhibiting a viral infection.
- Group VI: Claim 26, drawn to a method of screening a compound for reducing and inhibiting a viral infection using the product of Group I.
- Group VII: Claim 27, drawn to a method of suppressing a malignant phenotype.
- Group VIII: Claim 28, drawn to a method of screening a compound for effectiveness in treating a viral infection.
- Group IX: Claim 29, drawn to a method of screening a compound that can suppress a malignant phenotype in a cell.

As stated above, new claim 30 has been added. Therefore, Applicants elect Group IV which now corresponds to claim 24 and claim 30.



ATTORNEY DOCKET NO. 01123.0004
Serial No. 09/509,712

The Office Action states that Groups I-IV and VI are drawn to nucleotides and nucleotide constructs that contain more than ten individual, independent, and distinct nucleotide sequences in an alternative form. Accordingly, these claims are subject to restriction under 35 U.S.C. § 121. Therefore, the Office Action states that Applicant is required to select no more than ten of the individual sequences for examination.

The Office Action further states that Applicant is required to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable.

In a telephone conference with Dr. Lizette Fernandez, Examiner Foley indicated that Applicants were only required to elect ten sequences for examination in response to restriction under 35 U.S.C. § 121 and the species election. Therefore, Applicants elect SEQ ID NO: 19, SEQ ID NO: 30, SEQ ID NO: 40, SEQ ID NO: 51, SEQ ID NO: 60, SEQ ID NO: 65, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 109, SEQ ID NO: 122 for examination.

A check in the amount of \$945.00 and a Request for Extension of Time are enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Gwendolyn D. Spratt

Date

7-9-01